DOI QR코드

DOI QR Code

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma

  • Wen, Ru-Min (Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute) ;
  • Zhang, Yi-Jing (Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute) ;
  • Ma, Sha (Department of Hematology, the Affiliated Hospital of Xuzhou Medical College) ;
  • Xu, Ying-Li (Department of Operation, the Affiliated Hospital of Xuzhou Medical College) ;
  • Chen, Yan-Su (Department of Public health, Xuzhou Medical College) ;
  • Li, Hai-Long (Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute) ;
  • Bai, Jin (Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute) ;
  • Zheng, Jun-Nian (Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute)
  • 발행 : 2015.05.18

초록

Background: The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with colorectal, lung, gastric cancer, pancreatic and metastatic renal cell carcinoma. We here evaluated whether preoperative NLR is an independent prognostic factor for non-metastatic renal cell carcinoma (RCC). Materials and Methods: Data from 327 patients who underwent curative or palliative nephrectomy were evaluated retrospectively. In preoperative blood routine examination, neutrophils and lymphocytes were obtained. The predictive value of NLR for non-metastatic RCC was analyzed. Results: The NLR of 327 patients was $2.72{\pm}2.25$. NLR <1.7 and NLR ${\geq}1.7$ were classified as low and high NLR groups, respectively. Chi-square test showed that the preoperative NLR was significantly correlated with the tumor size (P=0.025), but not with the histological subtype (P=0.095)and the pT stage (P=0.283). Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. Effects of NLR on OS (P=0.007) and DFS (P=0.011) were significant. To evaluate the independent prognostic significance of NLR, multivariate COX regression models were applied and identified increased NLR as an independent prognostic factor for OS (P=0.015), and DFS (P=0.019). Conclusions: Regarding patient survival, an increased NLR represented an independent risk factor, which might reflect a higher risk for severe cardiovascular and other comorbidities. An elevated blood NLR may be a biomarker of poor OS and DFS in patients with non-metastatic RCC.

키워드

참고문헌

  1. Alkhouri N, Morris-Stiff G, Campbell C, et al (2012). Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int, 32, 297-302. https://doi.org/10.1111/j.1478-3231.2011.02639.x
  2. Atzpodien J, Royston P, Wandert T, et al (2003). Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer, 88, 348-53. https://doi.org/10.1038/sj.bjc.6600768
  3. Azab B, Jaglall N, Atallah JP, et al (2011). Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology, 11, 445-52. https://doi.org/10.1159/000331494
  4. Ceylan C, Camtosun A, Doluoglu OG, et al (2014). Emphasis of neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma. Urologia, 81, 51-6. https://doi.org/10.5301/urologia.5000032
  5. Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23. https://doi.org/10.1007/s00262-008-0516-3
  6. Cindolo L, de la Taille A, Messina G, et al (2003). A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int, 92, 901-5. https://doi.org/10.1111/j.1464-410X.2003.04505.x
  7. Donskov F, von der Maase H (2006). Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 24, 1997-2005. https://doi.org/10.1200/JCO.2005.03.9594
  8. Eryilmaz MK, Mutlu H, Salim DK, et al (2014). The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev, 15, 7737-40. https://doi.org/10.7314/APJCP.2014.15.18.7737
  9. Ficarra V, Brunelli M, Cheng L, et al (2010). Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol, 58, 655-68. https://doi.org/10.1016/j.eururo.2010.08.001
  10. Gerlinger M, Rowan AJ, Horswell S, et al (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 366, 883-92. https://doi.org/10.1056/NEJMoa1113205
  11. Gibson PH, Croal BL, Cuthbertson BH, et al (2007). Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J, 154, 995-1002. https://doi.org/10.1016/j.ahj.2007.06.043
  12. Grunwald V, Ravaud A (2014). Systemic therapy of renal cell carcinoma. World J Urol, 32, 1. https://doi.org/10.1007/s00345-013-1226-9
  13. Imtiaz F, Shafique K, Mirza SS, et al (2012). Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med, 5, 2. https://doi.org/10.1186/1755-7682-5-2
  14. Ishizuka M, Nagata H, Takagi K, et al (2013). Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer, 109, 401-7. https://doi.org/10.1038/bjc.2013.350
  15. Kattan MW, Reuter V, Motzer RJ, et al (2001). A postoperative prognostic nomogram for renal cell carcinoma. J Urol, 166, 63-7. https://doi.org/10.1016/S0022-5347(05)66077-6
  16. Keizman D, Ish-Shalom M, Huang P, et al (2012). The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer, 48, 202-8. https://doi.org/10.1016/j.ejca.2011.09.001
  17. Kim SP, Shah ND, Weight CJ, et al (2011). Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol, 186, 1779-85. https://doi.org/10.1016/j.juro.2011.07.041
  18. Leibovich BC, Blute ML, Cheville JC, et al (2003). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer, 97, 1663-71. https://doi.org/10.1002/cncr.11234
  19. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44. https://doi.org/10.1038/nature07205
  20. Ohno Y, Nakashima J, Ohori M, et al (2010). Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol, 184, 873-8. https://doi.org/10.1016/j.juro.2010.05.028
  21. Pedersen BK, Bruunsgaard H, Jensen M, et al (1999). Exercise and immune function: effect of ageing and nutrition. Proc Nutr Soc, 58, 733-42. https://doi.org/10.1017/S0029665199000968
  22. Pichler M, Hutterer GC, Chromecki TF, et al (2011). External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol, 186, 1773-7. https://doi.org/10.1016/j.juro.2011.07.034
  23. Proctor MJ, Morrison DS, Talwar D, et al (2011). A comparison of inflammation-based prognostic scores in patients with cancer. a glasgow inflammation outcome study. Eur J Cancer, 47, 2633-41. https://doi.org/10.1016/j.ejca.2011.03.028
  24. Roos FC, Steffens S, Junker K, et al (2014). Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer, 14, 372. https://doi.org/10.1186/1471-2407-14-372
  25. Roxburgh CS, McMillan DC (2010). Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol, 6, 149-63. https://doi.org/10.2217/fon.09.136
  26. Shuch BM, Lam JS, Belldegrun AS, et al (2006). Prognostic factors in renal cell carcinoma. Semin Oncol, 33, 563-75. https://doi.org/10.1053/j.seminoncol.2006.06.006
  27. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  28. Sun M, Bianchi M, Hansen J, et al (2012). Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol, 62, 696-703. https://doi.org/10.1016/j.eururo.2012.03.051
  29. Terradas R, Grau S, Blanch J, et al (2012). Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PLoS One, 7, 42860. https://doi.org/10.1371/journal.pone.0042860
  30. Tsai JC, Sheu SH, Chiu HC, et al (2007). Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 23, 111-8. https://doi.org/10.1002/dmrr.647
  31. Ubukata H, Motohashi G, Tabuchi T, et al (2010). Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol, 102, 742-7. https://doi.org/10.1002/jso.21725
  32. Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. https://doi.org/10.1002/jso.20329
  33. Zahorec R (2001). Ratio of neutrophil to lymphocyte countsrapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy, 102, 5-14.

피인용 문헌

  1. Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1399
  2. Value of the preoperative neutrophil-to-lymphocyte ratio as a prognostic factor for long-term survival in postoperative esophageal squamous cell carcinoma patients pp.17597706, 2018, https://doi.org/10.1111/1759-7714.12885
  3. Role of systemic inflammatory response markers in urological malignancy pp.09198172, 2019, https://doi.org/10.1111/iju.13801